Brind.

William Blair analyst questioned the strategic fit of Freenome's partnership.

2 reports, 1 independent Updated Aug 13

Gone quiet

Reports: 2
Developments: 2
Repetition: 0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

William Blair analyst questioned the strategic fit of Freenome's partnership.

Who's involved

What this event is mainly about

Exact Sciences William P. Blair

How it developed

Newest first. Tap a step to see who reported it.

Aug 13William Blair analyst questioned the strategic fit of a Freenome partnership.1 source
- StockStory
Aug 12Freenome/Exact Sciences partnership achieves commercial momentum with expanded coverage.1 source
- StockStory

Keep exploring

The entities involved

Exact Sciences
American company in Madison, United States
- Zacks Investment Research provided stock analysis and ratings for Exact Sciences.Sun 06:59
William P. Blair
American astrophysicist
- Watsco reported margin impacts due to subdued international sales in Mexico, with analysts questioning volume trends.Sun 06:23

Coverage

Newest first; wire copies grouped

Aug 13StockStoryThe Top 5 Analyst Questions From Exact Sciences’s Q2 Earnings Call Exact Sciences delivered a quarter characterized by strong year-over-year revenue growth and margin improvement, but the market resp
Aug 12StockStoryEXAS Q2 Deep Dive: Portfolio Expansion and Productivity Drive Guidance Increase Amid Market Caution Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue